After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or ...

In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...